Taken together, the fact that RCE as the PD-1/PD-L1 blockade and Oxa combination therapy provided significantly better tumor control in CRC than either therapy alone demonstrates the potential of chemotherapy regimens to improve the response to immune checkpoint blockade therapy in CRC. The gene discussed is CD274; the disease is neoplasm.